WaferGen Biosystems

WaferGen, now part of Takara Bio USA, Inc., specializes in providing advanced genomic technology solutions for single-cell analysis and clinical research. The company offers a range of innovative platforms, including the ICELL8® Single-Cell System, which isolates thousands of single cells for various analysis methods such as next-generation sequencing. This system can handle up to 1,800 single cells on a single chip, making it suitable for analyzing cells from solid tumors, brain tissues, pulmonary airway cells, and multiple cell lines.

The SmartChip™ platform is designed for profiling and validating molecular biomarkers and can perform massively parallel singleplex PCR for one-step NGS library preparation in clinical applications. Additionally, the Apollo™ 324 system processes DNA and RNA from clinical samples into NGS-ready libraries. These technologies serve the life sciences, pharmaceutical, and clinical laboratory industries, providing powerful tools for biological analysis at both the molecular and single-cell levels.

WaferGen's business model focuses on selling these specialized systems to research institutions, pharmaceutical companies, and clinical laboratories. Revenue is generated through the sale of these platforms and associated consumables, as well as through service contracts and support agreements. The company operates in a niche market that demands high precision and reliability, catering to clients who require advanced genomic analysis capabilities.

Keywords: genomic technology, single-cell analysis, clinical research, ICELL8®, SmartChip™, Apollo™ 324, next-generation sequencing, molecular biomarkers, DNA/RNA processing, life sciences.